Brought to you by 
Vyome gets $14mm via Series C
22 Aug 2016
Executive Summary
Indian-based Vyome Biosciences Pvt. Ltd. (therapies for skin diseases caused by resistant microbes) raised $14mm in its Series C financing led by Perceptive Advisors and Romulus Capital, which were joined by returning shareholders including Kalaari Capital, Sabre Partners, and Aarin Capital. The company will use the funds to continue developing its lead candidate VB1953, which is in IND-enabling studies for moderate-to-severe acne.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Topical Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vyome gets $14mm via Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice